Review article: withdrawal of 5‐aminosalicylates in inflammatory bowel disease
Alimentary Pharmacology & Therapeutics2020Vol. 52(1), pp. 73–84
Citations Over TimeTop 10% of 2020 papers
Abstract
Although the majority of patients with IBD receive 5-ASA during their disease course, safe withdrawal appears possible in many, with important implications for both health economics and patient experience. A number of unanswered questions, however, remain.
Related Papers
- → EPIDEMIOLOGY OF INFLAMMATORY BOWEL DISEASE(1995)60 cited
- → Influence of environmental factors on the onset and course of inflammatory bowel disease(2016)53 cited
- → Evaluation of bone mineral density in inflammatory bowel disease: current safety focus(2003)21 cited
- → Disease Modifiers in the Management of Ulcerative Colitis(2014)
- [The genetic basis of inflammatory bowel disease unravelled by genetic association studies].(2009)